Conventional versus ultrapure dialysate for lowering serum lipoprotein(a) levels in patients on long-term hemodialysis: A randomized trial

International Journal of Artificial Organs

Volumn 33, Issue 5, 2010, Pages 290-296

  Tao, Jianling ^a   Sun, Yang ^a   Li, Xuemei ^a   Li, Hang ^a   Liu, Shiqin ^a   Wen, Yubing ^a   Duan, Lin ^a   Li, Yan ^a   Li, Xuewang ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Atherosclerosis; Hemodialysis; Inflammation; Lipoprotein(a); Ultrapure dialysate

Indexed keywords

BODY FLUIDS; CARDIOLOGY; DISEASES; HEMODIALYZERS; LIPOPROTEINS;

CARDIOVASCULAR DISEASE; DIALYSATES; HAEMODIALYSIS; LIPOPROTEIN(A); LOW FLUX; POLYSULPHONE; RANDOMIZED TRIAL; RISK FACTORS; ULTRAPURE; ULTRAPURE DIALYZATE;

DIALYSIS;

ALBUMIN; BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; ENDOTOXIN; HEMOGLOBIN; INTERLEUKIN 6; LIPOPROTEIN A; POLYSULFONE; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVENTIONAL DIALYSIS; DIALYSATE; DIALYSIS MEMBRANE; FEMALE; HEMODIALYSIS; HUMAN; INTERMETHOD COMPARISON; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MALE; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; ULTRAFILTRATION; ULTRAPURE DIALYSIS;

EID: 77954649716     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139881003300504     Document Type: Article

References (19)

1. Longenecker JC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005; 16: 1794-1802.
2. Liu Y, Coresh J, Eustace JA, Longenecker JC, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291: 451-9. (Pubitemid 38129749)
3. Ouseph R, Jones S, Dhananjaya N, Ward RA. Use of ultrafiltered dialysate is associated with improvement in haemodialysis-associated morbidity in patients treated with reused dialysers. Nephrol Dial Transplant 2007; 22: 2269-75. (Pubitemid 47244705)
4. Masakane I. Review: Clinical usefulness of ultrapure dialysate - recent evidence and perspectives. Ther Apher Dial 2006; 10: 348-54. (Pubitemid 44154765)
5. Baz M, Durand C, Ragon A, et al. Using ultrapure water in hemodialysis delays carpal tunnel syndrome. Int J Artif Organs 1991; 14: 681-5.
6. Furuya R, Kumagai H, Takahashi M, Sano K, Hishida A. Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif 2005; 23: 311-6. (Pubitemid 41327803)
7. Schiffl H, Lang SM, Bergner A. Ultrapure dialysate reduces dose of recombinant human erythropoietin. Nephron 1999; 83: 278-9. (Pubitemid 29486411)
8. Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 2001; 16: 1863-9. (Pubitemid 32821419)
9. Schiffl H, Lang SM, Fischer R. Ultrapure dialysis fluid slows loss of residual renal function in new dialysis patients. Nephrol Dial Transplant 2002;17:1814-1818.
10. Lonnemann G. The quality of dialysate: an integrated approach. Kidney Int 2000; 58: S112-9.
11. Lamas JM, Alonso M, Sastre F, Garcia TG, Saavedra J, Palomares L. Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements - a randomized study. Nephrol Dial Transplant 2006; 21: 2851-8.
12. Memoli B. Cytokine production in haemodialysis. Blood Purif 1999; 17: 149-58.
13. Lonnemann G. Chronic inflammation in hemodialysis: the role of contaminated dialysate. Blood Purif 2000; 18: 214-23.
14. Vanholder R, Van Haeche E, Veys N, Ringoir S. Endotoxin transfer through dialysis membranes: small versus large pore membranes. Nephrol Dial Transplant 1992; 7: 333-9.
15. Sitter T, Bergner A, Schiffl H. Dialysate related cytokine induction and response to recombinant human erythropoietin in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1207-11. (Pubitemid 30487799)
16. Izuhara Y, Miyata T, Saito K, et al. Ultrapur dialysate decreases plasma pentosidine, a marker of "carbonyl stress". Am J Kidney Dis 2004; 43: 1024-9.
17. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998; 82: 52U-66U.
18. Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007; 71: 1036-43.
19. Emanuele E, Lusignani LS, Peros E, et al. Lipoprotein(a)-associated atherothrombotic risk in hemodialysis patients. Am J Nephrol 2004; 24: 221-9. (Pubitemid 38456632)